Kim Y D, Robinson D Y, Tomita J T
Diagnostics Division, Abbott Laboratories, North Chicago, Illinois 60064.
Cancer Res. 1988 Aug 15;48(16):4543-8.
A unique mouse hybridoma, PR92, was obtained using human prostate adenocarcinoma cell line DU145. The monoclonal antibody produced by the PR92 clone was reactive with DU145, MCF-7 (breast adenocarcinoma), and CHAGO (lung carcinoma), but not with normal cell lines and 16 other cell lines of cancerous origin. A homologous solid-phase sandwich radioimmunoassay (PR92-RIA) was developed utilizing PR92 monoclonal antibody. The PR92-RIA recognized unique antigen present in DU145 cell extract but did not detect 16 other known tumor-associated markers. In preliminary studies, the PR92-RIA measured greater than 5 units/ml level of PR92 monoclonal antibody-binding antigen in 23 of 31 (74%) serum specimens of active prostate cancer and 27 of 31 (87%) active breast carcinoma patients. Only 1 of 79 (1%) sex-matched normal donors and 1 of 57 (2%) benign disease control patients showed the serum antigen level greater than 5 units/ml. A high degree of correlation was observed between the PR92 antigen activity and the clinical status of four prostate and four breast cancer patients during therapeutic treatment. Thus, the PR92-RIA detects new tumor-associated antigen which may be useful in detection and monitoring of prostate and breast carcinoma patients.
利用人前列腺腺癌细胞系DU145获得了一种独特的小鼠杂交瘤PR92。PR92克隆产生的单克隆抗体与DU145、MCF-7（乳腺腺癌）和CHAGO（肺癌）有反应，但与正常细胞系以及其他16种癌源性细胞系无反应。利用PR92单克隆抗体开发了一种同源固相夹心放射免疫测定法（PR92-RIA）。PR92-RIA识别DU145细胞提取物中存在的独特抗原，但未检测到其他16种已知的肿瘤相关标志物。在初步研究中，PR92-RIA在31例（74%）前列腺癌活动期血清标本中的23例以及31例（87%）乳腺癌活动期患者中的27例中检测到PR92单克隆抗体结合抗原水平高于5单位/毫升。在79名（1%）性别匹配的正常供者和57名（2%）良性疾病对照患者中，只有1人血清抗原水平高于5单位/毫升。在治疗期间，观察到4例前列腺癌和4例乳腺癌患者的PR92抗原活性与临床状态之间存在高度相关性。因此，PR92-RIA可检测新的肿瘤相关抗原，这可能有助于前列腺癌和乳腺癌患者的检测和监测。
